Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Achieve Life Sciences, Inc. ACHV
$8.40
-$0.46 (-5.46%)
На 18:01, 12 мая 2023
-4.76%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
172580100.00000000
-
week52high
10.25
-
week52low
2.00
-
Revenue
0
-
P/E TTM
-3
-
Beta
1.51903100
-
EPS
-4.02000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Alliance Global Partners | Buy | 04 окт 2021 г. | |
| Oppenheimer | Outperform | 23 июн 2021 г. | |
| Maxim Group | Buy | 25 ноя 2020 г. | |
| Lake Street | Buy | 25 ноя 2020 г. | |
| H.C. Wainwright | Buy | 25 ноя 2020 г. | |
| Maxim Group | Buy | Buy | 16 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bencich John | A | 100000 | 100000 | 25 янв 2023 г. |
| Bencich John | A | 100000 | 100000 | 25 янв 2023 г. |
| JACOBS CINDY | A | 60000 | 60000 | 25 янв 2023 г. |
| JACOBS CINDY | A | 60000 | 60000 | 25 янв 2023 г. |
| Stewart Richard Alistair | A | 75000 | 75000 | 25 янв 2023 г. |
| Stewart Richard Alistair | A | 75000 | 75000 | 25 янв 2023 г. |
| Wan Jerry | A | 15000 | 15000 | 25 янв 2023 г. |
| Wan Jerry | A | 15000 | 15000 | 25 янв 2023 г. |
| Bencich John | A | 11000 | 11000 | 18 ноя 2022 г. |
| Bencich John | A | 36920 | 22000 | 18 ноя 2022 г. |
Новостная лента
Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
GlobeNewsWire
26 апр 2023 г. в 08:00
SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2023 financial results and provide an update on the cytisinicline development program on Tuesday, May 9, 2023 at 4:30 PM EDT.
Achieve: Late-Stage Biotech Developing Vaping And Smoking Cessation Drugs
Seeking Alpha
25 апр 2023 г. в 16:37
Achieve: Late-Stage Biotech Developing Vaping And Smoking Cessation Drugs.
Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
GlobeNewsWire
14 апр 2023 г. в 08:00
SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2023 Conference being held at the Seattle Convention Center April 25-26, 2023.
Achieve Life Sciences, Inc. (ACHV) Q4 2022 Earnings Call Transcript
Seeking Alpha
16 мар 2023 г. в 21:33
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Nicole Jones - Investor Relations John Bencich - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jerry Wan - Principal Accounting Officer Jaime Xinos - Executive Vice President, Commercial Conference Call Participants Thomas Flaten - Lake Street Capital Michael Higgins - Ladenburg Thalmann Francois Brisebois - Oppenheimer Operator Hello and welcome to the Achieve Life Sciences Fourth Quarter 2022 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Achieve Life Sciences: All Eyes On Phase 3 Data For Smoking Cessation Drug
Seeking Alpha
28 янв 2023 г. в 23:45
ORCA-2 phase 3 trial was a success where Cytisinicline has shown statistically significant improvement in quit rates and robust safety profile. Phase 3 ORCA-3 registration trial is ongoing, and we expect the data readout in 2Q 2023; we expect the results to be positive.